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Abbreviations and Acronyms
In the United States approximately 164,690 men will be newly diagnosed and an estimated 29,430 will die of prostate cancer. 1 Prostate cancer, especially in the patient at high risk, is a progressive disease (Appendix 1). 2e6 With ongoing advancements in imaging technology the ability to identify previously undetectable metastases may result in a shift in the definition of disease states and in improved outcomes.
Treatment options and regimens in patients with advanced prostate cancer (hormone na€ ıve and castration resistant) have increased in recent years and now include novel androgen axis inhibitors, immunotherapy, targeted a particle therapy and chemotherapy. 7 Six treatments of mCRPC and nmCRPC, all with different mechanisms of action and OS benefits, have been approved since 2010 (ie sipuleucel-T, cabazitaxel, abiraterone acetate plus prednisone, enzalutamide, 223 Ra and apalutamide). 8, 9 Additional therapies are being studied, such as poly-(adenosine diphosphate-ribose) polymerase and phosphoinositide 3-kinase/protein kinase B pathway inhibitors. Studies suggest that earlier detection of advanced disease in specific patient populations, coupled with these newer treatment options, will potentially increase the OS benefit in these patients, especially in correlation with improved predictive markers to help guide treatment selection. 10, 11 The development of metastases is a seminal event during prostate cancer progression since CRPC heralds potentially fatal disease. Although OS has improved from approximately 18 months to 3 years since the approval of new therapeutic agents, CRPC is invariably fatal. There are risk factors prognostic of worse outcomes. In a retrospective study of 205 patients with mCRPC advanced age, time since diagnosis, a greater number of bone metastases, higher PSA levels and shorter PSADT were associated with shorter OS. 12 
REVIEW OF PRIOR RADIOGRAPHIC ASSESSMENTS TO DETECT ADVANCED RECURRENCE GROUP RECOMMENDATIONS
The RADAR I Group initially convened to provide recommendations for the early identification of prostate cancer metastases. RADAR I recommended preferred traditional imaging modalities and specifically when and how often imaging should be performed ( fig. 1) . 13 Subsequently the RADAR II Group met to elaborate on the work of the original RADAR I Group and provide recommendations on the therapeutic sequencing, combining or layering of approved treatments in patients with metastatic prostate cancer in whom CRPC developed. 14 
METHODS
The RADAR III Group convened to evaluate the use of NGI modalities and review the rationale for obtaining specific scans, the frequency of imaging, interpreting imaging results and subsequent clinical usefulness, and finally proposing a clinical decision making treatment algorithm. RADAR III discussed accessibility and utilization among medical, radiation and urological oncologists in various practice settings (eg academic vs community and rural vs urban). Recommendations were made regarding prostate cancer nomenclature to accurately represent the changing landscape of imaging and subsequent treatment decision making. RADAR III acknowledges the limitations of making recommendations when level 1 evidence-based data are not yet available. However, given the rapid development and increased availability of these newer imaging modalities and since practitioners are faced with making clinical decisions, recommendations are needed. RADAR III, based on their expert opinion and clinical experience, provides guidance for using these NGIs.
Updates were made to the original RADAR I guidelines to include recommendations on emerging NGI technologies based on the specificity and sensitivity of published reports and real-world availability. RADAR III also acknowledged the importance of incorporating NGI into future clinical trial designs. Importantly it was agreed that earlier initiation of treatment may lead to better outcomes with optimal patient selection. More definitive clinical trials are required to determine the optimal utilization of NGI technologies.
NEXT GENERATION IMAGING MODALITIES
PET is a functional imaging technique that is able to detect metabolic activity, blood flow, apoptosis, etc. 15 The use of PET/CT in patients with prostate cancer has been advanced by the development of new radiotracers, including 18 F-FACBC, 11 C-choline, agents targeting PSMA, 18 F-FDHT and 11 C-acetate. 7, 16 These NGI PET/CT radiotracers allow for the detection of previously undetectable metastases by traditional imaging studies (CT and 99m Tc bone scans) due to improved sensitivity and specificity. Several of these NGI techniques have been approved by the FDA for use in patients with prostate cancer, including 18 F-FACBC, 11 C-choline, 18 F-NaF and 18 F-FDG. FDA approval generally signifies that the scans can be performed reproducibly and safely. Additionally, the FDA as well as reimbursement agencies generally require a demonstration of clinical usefulness via alterations in treatment decisions based on the use of the specific imaging modality. 15, 17 However, FDA approval for these scans does not necessarily mean that proven value in clinical practice has been established. Specifically it does not mandate that treatment decisions are altered in a fashion which leads to clinical benefit in a patient through efficacy, safety or quality of life. tracers demonstrated that 18 F-fluciclovine had greater ability to detect locally recurrent disease vs 18 F-choline, although the difference was not statistically significant. 20 In a prospective study of 89 patients comparing the accuracy of 18 F-FACBC and 11 C-choline PET/CT in patients undergoing prostatectomy who presented with biochemical relapse, 18 F-FACBC showed superior detection over 11 C-choline. When categorizing patients by PSA level, the percent of patients with positive findings were generally higher with 18 F-FACBC than with 11 C-choline (see table) . 21, 22 Limitations of 18 F-fluciclovine include unknown responsiveness to ADT, limited information regarding imaging in the CRPC setting and the overall limitations of potential variability in sensitivity and specificity as they relate to the location of metastases (eg PSA and PSADT). 11 C-choline has variable sensitivity and specificity for biochemical recurrence, especially at low PSA levels. 21 11 C-choline has limited availability due to its short half-life of 20.4 minutes, which requires an on-site cyclotron, which few centers in the United States possess.
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18 F-NaF. 18 F-NaF is a radioactive tracer that diffuses into bone, leading to an exchange of fluoride ions with hydroxide ions of the hydroxyapatite crystals, eventually forming fluorapatite. 25 18 F-NaF PET/CT has higher specificity and sensitivity than traditional bone scans or planar single photon emission CT. 26 Despite this, the CMS (Centers for Medicare and Medicaid Services) no longer reimburses 18 F-NaF for prostate cancer management.
Positron Emission Tomography/Computerized Tomography Prostate Specific Membrane Antigen Ligands Novel imaging modalities using radiolabeled tracers with PSMA, such as 68 Ga PSMA PET/CT, have shown promising results with best use for biochemical recurrence. 27, 28 A review of the literature generally favors PSMA based agents vs choline and fluciclovine to detect recurrence as a function of low PSA levels, although comparison studies have not been performed ( fig. 2) . 15 Based on the growing body of literature regarding its clinical usefulness, the availability of PSMA in the United States is limited but beginning to increase. 15 68 Ga-Prostate Specific Membrane Antigen. As rapidly developed and implemented at different centers and clinics in Europe, Australia, South America and the United States, 68 Ga-PSMA-HBED-CC (gallium citrate) is one of the more applied ligands in this class of small molecule inhibitors worldwide. It has high sensitivity (63% to 86%) and specificity (95% to 100%) even at low PSA levels based on In a systematic review and meta-analysis of reported predictors of positive 68 Ga-PSMA PET, and corresponding sensitivity and specificity profiles, 16 articles with a total of 1,309 patients were analyzed. 27 The overall percent of positive 68 Ga-PSMA PET among patients was 40% (95% CI 19e64) for primary staging and 76% (95% CI 66e85) for BCR. Positive 68 Ga-PSMA PET in patients with BCR increased with prePET PSA. For the PSA categories 0 to 0.2, 0.2 to 1, 1 to 2 and greater than 2 ng/ml 42%, 58%, 76% and 95% of scans, respectively, were positive. Shorter PSADT increased 68 Ga-PSMA PET positivity. Summary sensitivity and specificity were both 86% on per patient analysis, and summary sensitivity and specificity were 80% and 97%, respectively, on prelesion analysis. 27 A prospective survey of referring physicians showed that PSMA-11 PET/CT resulted in actually implemented management changes in 54 of 101 patients (53%) with prostate cancer and BCR. 32 In a study of 68 Ga-PSMA in 70 patients with BCR after radical prostatectomy with extended lymph node dissection the sites of recurrent disease included the prostatic fossa in 27%, pelvic lymph nodes in 14.3%, the fossa and pelvic lymph nodes in 4.3%, and outside the pelvis in 8.6%. 33 These results show that 68 Ga-PSMA is able to detect local, regional and distant metastatic disease even in patients with low PSA levels. The investigational nature of 68 Ga-PSMA as well as the requirement for a 68 Ga generator limits its current availability in the United States.
F-DCFBC.
18 F-DCFBC is a small molecule PSMA inhibitor which is useful for reliably detecting high grade (Gleason 8 and 9) and larger (1.1 ml or greater) primary tumors. 34 It displays little uptake in benign prostatic hyperplasia and, therefore, it may be useful to differentiate malignant from nonmalignant prostate tissues.
18 F-DCFPyL Prostate Specific Membrane Antigen.
18 FDCFPyL is a second-generation 18 F labeled PSMA agent. In a small comparative study of 68 Ga-PSMA in 14 patients with BCR the 18 F-DCFPyL scan was slightly more sensitive with higher tumor-tobackground ratios than 68 Ga-PSMA. 35 In that study 18 F-DCFPyL detected all of the suspicious lesions detected by 68 Ga-PSMA plus additional suspicious lesions in 3 of 14 patients, indicating high sensitivity for 18 F-DCFPyL. 15 Reprinted with permission from Elsevier. 36 This radiotracer has demonstrated usefulness for assessing androgen receptor blockade with second line antiandrogens.
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11 C-Acetate. In a pooled meta-analysis of 23 studies of 11 C-acetate PET this radiotracer had suboptimal 75.1% sensitivity to detect primary tumors, although it had high 93% specificity to identify the location of relapse. 40 Taking into account the complexity of imaging with this tracer and the short 20.4-minute half-life of 11 C, requiring synthesis on site, the availability of 11 C-acetate PET for prostate cancer imaging is limited. 40 The short half-life of the isotope requires a cyclotron on site and only a few centers in the United States have this access.
MEDICARE COVERAGE
Only a few NGI PET/CT scans are currently covered by Medicare (Appendix 2). As of early 2018 the CMS withdrew the NOPR (National Oncology PET Registry) program for 18 F-NaF PET/CT. The NOPR program was a collaboration of the ACRINÔ (American College of Radiology Imaging Network), the ACRÒ (American College of Radiology) and the AMI (Academy of Molecular Imaging) to ensure access to Medicare reimbursement for certain types of PET.
Whole body MRI, which has been used successfully in Europe, has shown good sensitivity and specificity for bone metastases. In the United States there are no established CPT codes for reimbursement for whole body MRI. 41 
DISCUSSION
Next Generation Imaging Potential Clinical Impact Disease evaluation following unsuccessful initial interventional therapy is critical as salvage therapies may be curative but may also be associated with morbidity and not beneficial if distant disease exists. Local recurrence of prostate cancer can be detected by multiparametric MRI with components such as anatomical T2-weighting and functional imaging (eg diffusion-weighted imaging and dynamic contrast-enhanced imaging). 7 However, local recurrences and distant metastases can be better confirmed by NGI. 10,11,42e45 However, NGI has the potential to enhance outcomes as it can allow for earlier therapy in a patient with low PSA, when theoretical cure or significant tumor reduction may lead to benefits. In 2018 this notion was still hypothesis generating and, thus, prospective trials are required to evaluate the efficacy and risks of such earlier interventions. However, a recently published, phase 2 study in patients with oligorecurrent prostate cancer suggests the benefit of early intervention. 11 The availability of NGI has the potential to redefine the traditionally accepted stages in prostate cancer progression. Many cases diagnosed as M0 hormone sensitive and M0 CRPC based on traditional scans would now be potentially upgraded as M1 hormone sensitive and M1 CRPC using the improved NGI techniques. 46e48 The PROSPER (Safety and Efficacy Study of Enzalutamide in Patients With Nonmetastatic Castration-Resistant Prostate Cancer) and SPARTAN (Study of Apalutamide in Men With NonMetastatic Castration-Resistant Prostate Cancer) trials now support the use of enzalutamide and apalutamide in men with M0 CRPC (also identified as nmCRPC). These studies applied traditional imaging to determine the M0 disease state and nmCRPC, and ascertain progression. It is the RADAR III opinion that NGI should be evaluated and could be useful for both M0 disease states.
RADAR III Group Next Generation Imaging Recommendations
The transition to advanced prostate cancer is of crucial clinical importance and NGI techniques allow for the early identification of previously undetectable prostate cancer metastases. No single NGI imaging scan can detect all metastases required for clinical decision making. Of all NGI tests considered 18 F-FACBC PET has the best combination of availability, specificity and sensitivity in the United States. PSMA PET/CT shows great diagnostic potential but likely will not be available for widespread use in the United States for several years, although it being regularly used in some other nations (eg Australia, New Zealand, Germany and Brazil). It also may be ideal to couple with the development of novel therapeutic radiopharmaceuticals targeted to PSMA. In general RADAR III recommends available NGI techniques but the use of these scans varies based on each stage of advanced disease ( fig. 3) . 13 The RADAR III group recommends FDA approved systemic therapy (sipuleucel-T, cabazitaxel, abiraterone acetate plus prednisone, enzalutamide and 223 Ra) in patients with confirmed M1 CRPC who are clinically deemed fit enough to undergo such treatment. 8 These treatments, which have proved to extend OS in men with mCRPC, require confirmation of metastatic disease on scan before being initiated.
In early 2018 the FDA approved apalutamide, a next generation androgen receptor inhibitor, for patients with M0 CRPC. A phase 3 SPARTAN trial of 1,207 men with nonmetastatic CRPC and PSADT 10 months or less demonstrated that median metastasisfree survival was 40.5 months with apalutamide compared to 16.2 months with placebo (p <0.001).
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Time to symptomatic progression was also significantly longer with apalutamide than with placebo.
There are also promising new treatments under development for patients with M0 CRPC, including earlier use of enzalutamide based on the positive PROSPER trial, for which expanded approval is currently being sought. Another agent, darolutamide, has the potential to help delay progression to metastatic disease. It will be important to consider the inclusion of NGI techniques in clinical trials involving these agents in the M0 setting.
Newly Diagnosed Patients. In patients newly diagnosed with suspected localized prostate cancer RADAR I recommended traditional CT/bone scans in men who had at least 2 of the 3 certain criteria, including PSA level greater than 10 ng/ml, Gleason score 7 or greater and palpable disease (T2b or greater).
RADAR III recommends performing traditional scans with consideration for NGI only if the traditional scans are equivocal or negative and the clinician still suspects disease progression based on various factors. These factors include but are not limited to certain criteria, including Gleason score, PSA levels and PSA velocity in untreated patients while patients who meet NCCNÒ (National Comprehensive Cancer NetworkÒ) very high risk or locally advanced/N1 disease criteria should be considered for NGI at initial diagnosis. 42 As an example, consider a healthy 63-year-old male with PSA 60 ng/ml, Gleason score 7 in 10 of 12 cores, and negative 99m Tc bone scan and pelvic CT. We would recommend a NGI evaluation.
Although there is currently a lack of level 1 evidence to support the use of NGI, emerging clinical data support this approach. A recently published, prospective, phase 2 PMSA targeted PET/CT study was able to detect prostate cancer metastases in patients thought to have clinically localized disease based on traditional imaging, who thereby proceeded to interventional therapy. 49 Patients with Biochemical Recurrence. In patients with BCR who have been definitively treated RADAR III suggests that NGI may be considered in those with PSA 0.5 ng/ml or greater after treatment. Patients with PSA less than 0.5 ng/ml can be considered based on the specific performance of various NGI techniques. NGI should only be performed if the patient is willing to undergo metastasis directed therapy in the event of a positive scan or he is seeking a rationale to initiate systemic therapy. If a scan is not performed, PSA should be monitored closely and NGI should be reconsidered if PSA rises.
Patients with M0 Castration Resistance. In patients with M0 CRPC RADAR I recommended that a CT/ bone scan should be performed when PSA is 2 ng/ml or greater. If negative, subsequent scans should be performed when PSA is 5 ng/ml and at every doubling of PSA thereafter based on PSA testing every 3 months.
RADAR III reviewed NGI for M0 CRPC. NGI could identify metastases earlier, which would enable patients to receive treatment with the 5 agents which have regulatory approval in the M1 CRPC setting. Although to our knowledge earlier intervention using this approach has not been validated in prospective clinical trials, evidence supports the concept that intervening earlier with systemic therapies for M1 CRPC (sipuleucel-T) and for M0 CRPC (apalutamide) when the disease burden is lower may have a positive impact in some patients.
RADAR III suggests followup imaging every 6 to 12 months or more frequently based on less than 6-month PSADT and/or symptoms in patients undergoing therapy for M0 CRPC. If traditional imaging fails to detect metastatic disease, NGI can be performed only if approved therapies in the M1 space are being considered. RADAR III cautions against ceasing therapy for a PSA rise alone.
Given the recent approval of apalutamide for M0 disease, the value of NGI in this setting has yet to be determined. Thus, NGI should only be considered when disease progresses and M1 disease treatments are being considered. RADAR III expanded the original RADAR I recommendations to include additional guidance on imaging techniques for patients with M1 disease. The expanded recommendations include imaging using traditional scans and moving on to NGI only if the traditional scans are negative and the clinician still suspects disease progression based on at least 1 of certain factors, including with every doubling of PSA since the previous image was obtained, every 6 to 9 months in the absence of a PSA rise, or a change in symptomatology or performance status.
The goal of scanning in the M1 setting is to confirm disease progression to inform clinical decision making. If disease progression is confirmed on scan, RADAR III recommends considering therapeutic layering. Therapeutic layering is different from combination therapy, in which 2 or more therapies are initiated simultaneously. As defined by the RADAR II Group, therapeutic layering represents a clinical point at which 1 or more agent(s) are added to an existing therapy. In CRPC all treatment interventions are technically therapy layering since agents are added to the foundation of ADT. The RADAR II study provides specific recommendations on therapeutic layering in patients with M1 CRPC. 14 To our knowledge the use of NGI regarding the treatment response remains to be definitively established. Limitations include a comparison of NGI and nonNGI techniques as well as the significance of NGI semiquantitative analysis.
CONSIDERATIONS FOR NOMENCLATURE CHANGE
The heterogeneous nature of prostate cancer requires better terminology which more clearly defines the response to specific therapies. As the disease has continued to evolve biologically during the years in a much different way, our recommendation is to rename CRPC as ERPC.
Clinicians create an iatrogenic disease state by treating men with ADT who have rising PSA after local treatment. Once men show progression after ADT, endocrine resistance has developed and, if no metastasis is detected, they are categorized with M0 disease or nmCRPC. The original intent of the term CRPC was to describe metastatic disease while ADT is failing. Consequently M0 CRPC was added to categorize these men.
Two major advances have occurred which suggest the need to redefine this entire disease state. The first advance is NGI, which offers the opportunity to more accurately assess disease progression. Secondly 2 trials have demonstrated a significant benefit to newer third generation antiandrogen in the nonmetastatic endocrine resistant state. RADAR III believes that these events dictate the need to reassess and develop renewed nomenclature and guidelines.
Our recommendations are to now name these states as ERPC instead of CRPC. The rationale for this terminology was suggested several years ago. 50 There are certain RADAR III guidelines for this ERPC space. 1) Cases showing PSA or other signs of progression after adequate ADT of any stage of prostate cancer should be labeled as ERPC. 2) Cases of progression after adequate ADT of biochemical progression and negative conventional imaging should be labeled nmERPC (nonmetastatic conventional imaging), nmERPC* (nonmetastatic *NGI performed and since nmERPC* nonmetastatic by NGI). 3) A similar system should be used for positive imaging mERPC, mERPC* (metastatic by NGI) for metastatic disease. We believe that these guidelines would better stratify men for future evaluations.
In M1 disease the results of conventional scans may differ from those of NGI based on the dynamic and changing biology of the prostate cancer. Further head-to-head studies are warranted to investigate the different implications of appropriate therapeutic approaches.
CONCLUSIONS
While traditional CT, MRI and bone scans still have a role in initially diagnosing and/or staging prostate cancer, NGI modalities are more sensitive to visualize advanced prostate cancer. These new scans are recommended in select patients in whom aggressive intervention may be indicated earlier. Currently 18 F-FACBC PET is the NGI technique with the best combination of availability, specificity and sensitivity in the United States. PSMA PET/CT shows diagnostic potential but it likely will not be available for widespread use in the United States for several years.
Our strongest recommendation for NGI use is in patients with biochemically recurrent prostate cancer. This is where the data are strongest and the likelihood of site directed therapy is greatest in patients who are interested in such strategies. We recognize the lack of current efficacy and safety data but the purpose of a consensus study is to provide guidance in an area where clinical decision making is less than certain. Thus, we believe that the greatest potential impact to alter therapy and improve patient outcomes with NGI is in a setting where the reintroduction of local therapy with or without systemic therapy has the greatest potential.
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